Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis

Abstract

<b><i>Background:</i></b> This study aimed to evaluate the updated disease burden, risk factors, and temporal trends of liver cancer based on age, sex, and country. <b><i>Methods:</i></b> We estimated the incidence of liver cancer and its attribution to hepatitis B virus (HBV) and hepatitis C virus (HCV) in 2018 based on the Global Cancer Observatory and World Health Organization (WHO) Cancer Causes database<i>.</i> We extracted the prevalence of risk factors from the WHO Global Health Observatory to examine the associations by weighted linear regression. The trend analysis used data from the <i>Cancer Incidence in Five Continents</i> and the WHO mortality database from 48 countries. Temporal patterns of incidence and mortality were calculated using average annual percent change (AAPC) by joinpoint regression analysis. <b><i>Results:</i></b> The global incidence of liver cancer was (age-standardized rate [ASR]) 9.3 per 100,000 population in 2018, and there was an evident disparity in the incidence related to HBV (ASR 0.2–41.2) and HCV (ASR 0.4–43.5). A higher HCV/HBV-related incidence ratio was associated with a higher level of alcohol consumption (β 0.49), overweight (β 0.51), obesity (β 0.64), elevated cholesterol (β 0.70), gross domestic product (β 0.20), and Human Development Index (HDI; β 0.45). An increasing trend in incidence was identified in many countries, especially for male individuals, population aged ≥50 years, and countries with a higher HCV/HBV-related liver cancer incidence ratio. Countries with the most drastic increase in male incidence were reported in India (AAPC 7.70), Ireland (AAPC 5.60), Sweden (AAPC 5.72), the UK (AAPC 5.59), and Norway (AAPC 4.87). <b><i>Conclusion:</i></b> We observed an overall increasing trend of liver cancer, especially among male subjects, older individuals, and countries with a higher prevalence of HCV-related liver cancer. More efforts are needed in enhancing lifestyle modifications and accessibility of antiviral treatment for these populations. Future studies should investigate the reasons behind these epidemiological changes.

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

“…HCC was diagnosed by pathologic identification or dynamic imaging of abdominal computed tomography (CT) or magnetic resonance imaging (MRI) according to international HCC guidelines. The inclusion criteria were (1)…”

“…Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths worldwide, accounting for approximately 700,000 mortalities per year ( 1 ). HCC at early stage can often be curatively treated by effective options such as surgical resection, liver transplantation, and local ablation, which could lead to better survival outcome ( 2 ).…”

Global pattern of trends in incidence, mortality, and mortality-to-incidence ratio rates related to liver cancer, 1990–2019: a longitudinal analysis based on the global burden of disease study

“…Over the past decades, liver cancer has been known as one of the primary lethal neoplasms which has a widespread distribution across the globe with a serious threat to the public health [ 33 ]. The present paper provided strong evidence that the patterns of LC [1-MIR] rates and its components were extremely diverse among world super-regions for both genders from 1990 through 2019.…”

The Role of Protein SUMOylation in Human Hepatocellular Carcinoma: A Potential Target of New Drug Discovery and Development

“…In the past few decades, the incidence of HCC-related deaths has increased. Globally, it is estimated that more than 90,000 new cases of HCC and more than 20,000 deaths related to HCC in 2020 [ 2 ]. The prognosis of hepatocellular carcinoma is poor, with a 3-year survival rate of around 16.6% [ 3 ].…”